Analysis of retinal layer thickness in diabetic macular oedema treated with ranibizumab or triamcinolone

Acta Ophthalmologica

Volumn 96, Issue 2, 2018, Pages e195-e200

  Prager, Sonja G ^a   Lammer, Jan ^a   Mitsch, Christoph ^a   Hafner, Julia ^a   Pemp, Berthold ^a   Scholda, Christoph ^a   Kundi, Michael ^a   Schmidt Erfurth, Ursula ^a   Kriechbaum, Katharina ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

diabetic macular oedema; ganglion cell layer; ranibizumab; segmentation; spectral domain optical coherence tomography; triamcinolone

Indexed keywords

RANIBIZUMAB; TRIAMCINOLONE; ANGIOGENESIS INHIBITOR; GLUCOCORTICOID; TRIAMCINOLONE ACETONIDE; VASCULOTROPIN A; VEGFA PROTEIN, HUMAN;

ADULT; ARTICLE; CLINICAL ARTICLE; CORRELATIONAL STUDY; DIABETIC MACULAR EDEMA; FEMALE; FOLLOW UP; HUMAN; IMAGE SEGMENTATION; MALE; PRIORITY JOURNAL; RETINAL GANGLION CELL LAYER; RETINAL NERVE FIBER LAYER THICKNESS; SPECTRAL DOMAIN OPTICAL COHERENCE TOMOGRAPHY; VISUAL ACUITY; AGED; ANTAGONISTS AND INHIBITORS; COMPARATIVE STUDY; CONTROLLED STUDY; DIABETIC RETINOPATHY; DOUBLE BLIND PROCEDURE; INTRAVITREAL DRUG ADMINISTRATION; MACULAR EDEMA; MIDDLE AGED; NERVE FIBER; OPTICAL COHERENCE TOMOGRAPHY; ORGAN SIZE; PATHOLOGY; PATHOPHYSIOLOGY; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RETINA GANGLION CELL;

AGED; ANGIOGENESIS INHIBITORS; DIABETIC RETINOPATHY; DOUBLE-BLIND METHOD; FEMALE; GLUCOCORTICOIDS; HUMANS; INTRAVITREAL INJECTIONS; MACULAR EDEMA; MALE; MIDDLE AGED; NERVE FIBERS; ORGAN SIZE; PROSPECTIVE STUDIES; RANIBIZUMAB; RETINAL GANGLION CELLS; TOMOGRAPHY, OPTICAL COHERENCE; TRIAMCINOLONE ACETONIDE; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VISUAL ACUITY;

EID: 85042007048     PISSN: 1755375X     EISSN: 17553768     Source Type: Journal    
DOI: 10.1111/aos.13520     Document Type: Article

References (27)

1. Bonnin S, Tadayoni R, Erginay A, Massin P & Dupas B (2015): Correlation between ganglion cell layer thinning and poor visual function after resolution of diabetic macular edema. Invest Ophthalmol Vis Sci 56: 978–982.
2. Bussel II, Wollstein G & Schuman JS (2014): OCT for glaucoma diagnosis, screening and detection of glaucoma progression. Br J Ophthalmol 98: 15–19.
3. Chhablani J, Sharma A, Goud A, Peguda HK, Rao HL, Begum VU & Barteselli G (2015): Neurodegeneration in type 2 diabetes: evidence from spectral-domain optical coherence tomography. Invest Ophthalmol Vis Sci 56: 6333.
4. Ctori I & Huntjens B (2015): Repeatability of foveal measurements using spectralis optical coherence tomography segmentation software. PLoS ONE 10: e0129005.
5. Deák GG, Bolz M, Ritter M, Prager S, Benesch T & Schmidt-Erfurth U (2010): A systematic correlation between morphology and functional alterations in diabetic macular edema. Invest Ophthalmol Vis Sci 51: 6710–6714.
6. van Dijk HW, Verbraak FD, Kok PHB et al. (2012): Early neurodegeneration in the retina of type 2 diabetic patients. Invest Ophthalmol Vis Sci 53: 2715–2719.
7. Ebneter A, Wolf S, Abhishek J & Zinkernagel MS (2016): Retinal layer response to ranibizumab during treatment of diabetic macular edema thinner is not always better. Retina 36: 1314–1323.
8. Garcia-martin E, Larrosa JM, Polo V et al. (2014): Distribution of retinal layer atrophy in patients with Parkinson disease and association with disease severity and duration. Am J Ophthalmol 157: 470–478. e2.
9. Hwang DJ, Lee EJ, Lee SY, Park KH & Woo SJ (2014): Effect of diabetic macular edema on peripapillary retinal nerve fiber layer thickness profiles. Invest Ophthalmol Vis Sci 55: 4213–4219.
10. Jeoung JW, Choi YJ, Park KH & Kim DM (2016): Macular ganglion cell imaging study : glaucoma diagnostic accuracy of spectral-domain optical coherence tomography.
11. Kim BY, Smith SD & Kaiser PK (2006): Optical coherence tomographic patterns of diabetic macular edema. Am J Ophthalmol 142: 405–412.
12. Kobayashi W, Kunikata H, Omodaka K et al. (2015): Correlation of papillomacular nerve fiber bundle thickness with central visual function in open-angle glaucoma. J Ophthalmol 2015: 460918.
13. Kriechbaum K, Prager S, Mylonas G, Scholda C, Rainer G, Funk M, Kundi M & Schmidt-Erfurth U (2014): Intravitreal bevacizumab (Avastin) versus triamcinolone (Volon A) for treatment of diabetic macular edema: one-year results. Eye (Lond) 28: 9–16.
14. Kupersmith MJ, Kardon R, Durbin M, Horne M & Shulman J (2012): Scanning laser polarimetry reveals status of RNFL integrity in eyes with optic nerve head swelling by OCT. Invest Ophthalmol Vis Sci 53: 1962–1970.
15. Loss F, Shin H, Park HL, Jung K & Choi J (2013): Glaucoma diagnostic ability of ganglion cell e inner plexiform layer thickness differs according to the location of visual. Ophthalmology 121: 93–99.
16. Massin P, Bandello F, Garweg JG et al. (2010): Safety and efficacy of ranibizumab in diabetic macular edema (RESOLVE Study): a 12-month, randomized, controlled, double-masked, multicenter phase II study. Diabetes Care 33: 2399–2405.
17. Mitchell P, Bandello F, Schmidt-Erfurth U et al. (2011): The RESTORE study: ranibizumab monotherapy or combined with laser versus laser monotherapy for diabetic macular edema. Ophthalmology 118: 615–625.
18. Nguyen QD, Shah SM, Khwaja AA et al. (2010): Two-year outcomes of the ranibizumab for edema of the mAcula in diabetes (READ-2) study. Ophthalmology 117: 2146–2151.
19. Nunes S, Pereira I, Santos A, Bernardes R & Cunha-Vaz J (2010): Central retinal thickness measured with HD-OCT shows a weak correlation with visual acuity in eyes with CSME. Br J Ophthalmol 94: 1201–1204.
20. Pemp B, Palkovits S, Sacu S, Schmetterer L & Schmidt-Erfurth U (2015): Analysis of neurodegeneration of single retinal layers using optical coherence tomography in non-proliferative diabetic retinopathy. Spekt Augenehilkunde 29: 108.
21. Rebolleda G, Sanchez-Sanchez C, Gonzalez-Lopez JJ, Contreras I & Munoz-Negrete FJ (2015): Papillomacular bundle and inner retinal thicknesses correlate with visual acuity in nonarteritic anterior ischemic optic neuropathy. Invest Ophthalmol Vis Sci 56: 682–692.
22. Shin HJ, Hyen LS, Chung H & Kim HC (2012): Association between photoreceptor integrity and visual outcome in diabetic macular edema. Graefes Arch Clin Exp Ophthalmol 250: 61–70.
23. Simó R & Hernández C (2012): Neurodegeneration is an early event in diabetic retinopathy: therapeutic implications. Br J Ophthalmol 96: 1285–1290.
24. Sk D, Boptom N, Chiang PPC, Mrcs GT, Gemmy M, Mbbs C, Cheng CY & Carol Y (n.d.). Retinal ganglion cell neuronal damage in diabetes and diabetic retinopathy.
25. Sun JK, Radwan SH, Soliman AZ et al. (2015): Neural retinal disorganization as a robust marker of visual acuity in current and resolved diabetic macular edema. Diabetes 64: 2560–2570.
26. Sun JK, Lin MM, Lammer J, Prager S, Sarangi R, Silva PS & Aiello LP (2016): Disorganization of the retinal inner layers as a predictor of visual acuity in eyes with center-involved diabetic macular edema. JAMA Ophthalmol. 132: 1309–1316.
27. The Diabetic Retinopathy Clinical Research Network (2015): Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema. N Engl J Med 372: 1193–1203.